Search hospitals > New Jersey > Englewood
Englewood Hospital and Medical Center
Claim this profileEnglewood, New Jersey 07631
Global Leader in Breast Cancer
Global Leader in Breast cancer
Conducts research for Pancreatic Cancer
Conducts research for Lung Cancer
Conducts research for Coronary Artery Disease
149 reported clinical trials
12 medical researchers
Summary
Englewood Hospital and Medical Center is a medical facility located in Englewood, New Jersey. This center is recognized for care of Breast Cancer, Breast cancer, Pancreatic Cancer, Lung Cancer, Coronary Artery Disease and other specialties. Englewood Hospital and Medical Center is involved with conducting 149 clinical trials across 244 conditions. There are 12 research doctors associated with this hospital, such as Steven Elias, MD, Jill Morrison, MD, Minaxi Jhawer, and David M. Dubin.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
2Breast Cancer
Global LeaderHER2 positive
HER2 negative
ER positive
Top PIs
Steven Elias, MDEnglewood Hospital and Medical Center4 years of reported clinical research
Studies Varicose Veins
Studies Venous Leg Ulcer
6 reported clinical trials
9 drugs studied
Jill Morrison, MDEnglewood Hospital and Medical Center2 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
6 reported clinical trials
19 drugs studied
Minaxi JhawerEnglewood Hospital and Medical Center6 years of reported clinical research
Studies Colorectal Cancer
Studies Pancreatic Cancer
4 reported clinical trials
11 drugs studied
David M. DubinEnglewood Hospital and Medical Center11 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
3 reported clinical trials
8 drugs studied
Clinical Trials running at Englewood Hospital and Medical Center
Lung Cancer
Breast Cancer
Coronary Artery Disease
Pancreatic Cancer
Esophageal cancer
Breast cancer
Bladder Cancer
Esophageal Cancer
Gliosarcoma
Glioblastoma
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
MK-2870
for Non-Small Cell Lung Cancer
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypotheses are that sacituzumab tirumotecan is: (1) superior to chemotherapy with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by BICR in NSCLC with EGFR mutations; and (2) superior to chemotherapy with respect to overall survival (OS) in NSCLC with EGFR mutations.
Recruiting2 awards Phase 39 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Englewood Hospital and Medical Center?
Englewood Hospital and Medical Center is a medical facility located in Englewood, New Jersey. This center is recognized for care of Breast Cancer, Breast cancer, Pancreatic Cancer, Lung Cancer, Coronary Artery Disease and other specialties. Englewood Hospital and Medical Center is involved with conducting 149 clinical trials across 244 conditions. There are 12 research doctors associated with this hospital, such as Steven Elias, MD, Jill Morrison, MD, Minaxi Jhawer, and David M. Dubin.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.